involved 38 histopathologically proved DTC patients underwent total thyroid ablation with elevated serum TG and negative I-131 WBS during follow up. Significantly higher overall accuracy, sensitivity & NPV were found in stimulated group (98.5%, 88.6%, 62% respectively) compared to the suppressed group (66%, 62% & 31.5% respectively) that was more obvious in nodal rather than pulmonary deposits (P<0.05). However no significant difference was demonstrated in specificity & PPV between both groups. Significantly lower TG cut off point was demonstrated in stimulated group (15 ng/ml) compared to suppressed group (21 ng/ml) (P<0.05). Moreover significantly higher impact of F-18 FDG PET-CT in TSH stimulated (40%) was demonstrated compared to TSH suppressed (11.2%) group on patient management.
Conclusion:
High TSH seems to enhance F-18 FDG PET/CT efficiency on nodal rather than pulmonary metastases in recurrent DTC patients with elevated serum TG level and negative I-131 WBS. Moreover it reduces TG cut off point for F-18 FDG PET-CT & escalates its impact on patient management.
INTRODUCTION
Recurrent differentiated thyroid carcinoma (DTC) with elevated serum thyroglobulin (TG) level and negative I-131 WBS represents a diagnostic and therapeutic dilemma in clinical practice. This subset of tumor recurrence called dedifferentiated thyroid carcinoma (De-DTC) in which cellular de-differentiation and tumour progression may occurs (1, 2) . De-differentiation is genetically based complex process produces multiple molecular changes that progressively transform differentiated tumor into dedifferentiated one with more aggressive behavior and characteristics. These include more aggressive growth, enhanced invasive activity, angio-genesis and increased metastatic spread as well as inability to concentrate radio-iodine (RAI). The latter cause high false negative radio-iodine WBS and making the disease resistant to RA I-131 therapy. In such patients with low diagnostic and therapeutic yield for RAI, precise localization of tumor site is essential to define the therapeutic strategy particularly when surgery is purposed as a curative intent (3, 4, 5, 6, 7, 8, 9, 10) . Therefore strong need for an alternative effective imaging tool that can predict and detect dedifferentiated lesions is clinically desired. Unsatisfactory results has been reported in the literature regarding the use of conventional morphologic imaging procedures to localize tumour deposits in recurrent De-DTC patients with elevated serum TG levels & in the absence of thyroglobulin auto-antibodies. In contrast various molecular & clinical studies demonstrate the effectiveness of F-18 FDG PET/CT in localization of recurrent de-differentiated thyroid carcinoma lesions in those patients. The biological basis of that include up regulation of glucose consumption via over-expressed trans-membrane receptor GlUT-1 by these lesions. On the other hand, the impact of high TSH level on the effectiveness of F-18-FDG PET/CT imaging in recurrent de-differentiated thyroid cancer is not completely certain and lack of agreement is reflected in published data (8, 11, 12, 13, 14, 15) .
The fore mentioned considerations, besides the incongruity in the published data regarding the value of high TSH level on F-18 FDG PET/CT results in dedifferentiated thyroid carcinoma patients with elevated serum TG and negative I-131 WBS, encouraged us to perform the current prospective study. The objectives are; firstly to assess the value of TSH level on the results of F-18 FDG PET/CT in recurrent De-DTC with elevated TG level and negative I-131 WBS and to elucidate its impact on patient management. Secondly to determine its influence on the level of serum TG cut off point that yields the best compromise between sensitivity & specificity for F-18 FDG PET/CT results in these patients.
MATERIAL & METHODS
This study was approved by the ethics committee of the board of nuclear medicine & radiology at the cancer oncology center of Nasser institute hospital, Cairo, Egypt. Informed consent was obtained from all patients or their relatives with a full description of the procedures. This prospective work involved 38 consecutive patients with a median age of 48.5 years (range 22-75 years). All patients were investigated at the nuclear medicine unit in Nasser oncology center during the period from December 2010 till October 2012.
Patients had the following inclusion criteria: histopathologically proved differentiated thyroid carcinoma, age above 18 year old, underwent total radiosurgical thyroid ablation, rising serum TG levels above 10ng/ml in patients with stimulated TSH level as determined by immunechemil-uminescence test during follow up and negative I-131 WBS. 
Procedures:
Iodine -131 whole body scanning: Primary diagnostic or post-.therapeutic I-131 whole body scanning was performed 48 hours or 1 week following oral administration of radio-active I-131 using standard protocol respectively. Thyroid hormone replacement therapy was discontinued for all patients for 4 weeks, aiming at elevating serum thyroid stimulating hormone (TSH) levels above 30mIU/L.
Thyroglobulin Measurement
Blood samples for measuring serum TG levels were obtained from all patients. FDG-PET/CT procedure was performed following 4 weeks off-thyroxin therapy (stimulated group) (TSH >30 IU/L) while in the remaining 18 patient (47.4%) it was performed while onthyroxin therapy (suppressed group) (TSH <0.1 IU/L). Two expert nuclear medicine & radiological physicians who were unaware of clinco-pathological details or other radiological data evaluated the images for local recurrence and/or distant metastases.
Image analysis :
F-18 FDG PET/CT images were assessed for presence or absence of tumor deposits by using a five-point grading system in which the lesion uptake was compared to liver uptake as follow:-0 (no uptake): the lesion was definitely negative; 1 (lesion uptake < liver uptake): the lesion was probably negative; 2 (lesion uptake = liver uptake): the lesion was equivocal; 3 (lesion uptake slightly higher than live): the lesion was probably positive l;4 (intense lesion uptake that significantly higher than liver): the lesion was definitely positive. Determination of true or false positive or negative lesions were based on visual grading score, histopathology & FU data including clinic-radiological or F-18 FDG-PETCT as follow :  True-positive: score was 2-4 and histopathology was positive or it showed progression at follow-up sessions.  True-negative :score was 0-1 and histology was negative or follow-up examinations did not show any pathologic result in the region of concern for at least 12-18 mo.  False-positive: score was 2-4 and histopathology was negative or it showed no progression at follow-up sessions.  False-negative: score was 0-1 and histology was positive or follow-up examinations showed growth of the lesion(s).
Determination of Regional Abnormities:-
To compare F-18 FDG PET & fused PET-CT results with clinic-pathological data, the body was divided into two selected areas based on lesion site as follows:-Loco-regional area: including the neck region (enclosing the thyroid bed & cervical nodes) and superior mediastinal region for lymph nodes. Distant areas: including the rest of the mediastinal nodes, lungs, soft tissue & bone lesions.
Statistical Analysis:
Sensitivity, specificity, positive & negative predictive values as well as receiver operating characteristic (ROC) analysis were calculated using the Willson score which was generated by the open Epi program. The values are expressed as mean ± standard deviation (SD) The significance of the correlations was assessed with the Fisher z test. In addition, the multiple comparisons were adjusted by using the Bonferroni-Holm method. P values of less than 0.05 were considered to indicate significant differences.
RESULTS:
Based on the level of TSH at time of PET-CT procedure the patients were subdivided into two main groups: (Table 1) .
On bases of histo-pathological & follow up data for 12-18 months, a total of 79 & 100 lesions were documented in TSH stimulated & TSH suppressed groups respectively. 104 loco-regional lesions were confirmed pathologically (75 via post-operative histopathology while 29 lesions were confirmed through FNABC). The remaining 75 lesions were confirmed by monitoring their progressive course during follow up period for at least 12 months. As indicated in Table 2 
III. Change in restaging in recurrent
De-DTC patients: -In comparison to CT , the added value of F-18 FDG PET/CT in respect to restaging of recurrent De-DTC patients was significantly higher in TSH stimulated (40%) compared to TSH suppressed (11.2%) group (P<0.05) ( Table 5 ). In TSH stimulated group a more numerable number of nodal lesions were detected compared to CT. Therefore Up-staging was noticed in 6 patients (2 patients changes from N0 to N1a (Figure 2) , 2 from N0 to N1b & 2 patients from N1a to N1b) while down staging occurs in two patient from N1b to N1a. In TSH suppressed group, down staging was noticed in two patients from N1b to N0.
The added value of CT compared to PET/CT was significantly lower in TSH stimulated 5% compared to TSH suppressed group (16.6%) in the form of over-staging. This influence was noticed in detection of more number of pulmonary (Figure 3 ) rather than nodal lesions (Figure4).
DISCUSSION
The appropriate diagnostic consensus that assures the best yield in terms of high diagnostic accuracy and cost effectiveness of F-18-FDG PET/CT in respect to serum TG level in detection of recurrence in De-DTC patients with rising TG level and negative I-131 WBS is not achieved yet. Moreover the impact of high TSH level on effectiveness of FDG PET/CT in such diagnostic consensus is not completely certain and lack of agreement is reflected in published data (8, 13, 14, 15) . It was possible in the present study to assess the effects of TSH level on the results of F-18-FDG PET-CT in recurrent de-differentiated thyroid carcinoma patients with elevated TG level and negative I-131 WBS and to elucidate its impact on patient management. Moreover to determine a correlation between variations in TSH level and the values of serum TG cut off point in these patients. TSH in differentiated cancer thyroid stimulates metabolism, glucose transport & glycolysis of malignant thyroid cells. Moreover it works as a growth factor for malignant thyroid cells through stimulation of tumour growth, invasion and angiogenesis. *n = number ** Tn= total number *** Sup. Med = superior mediastinum **** NPV = negative predictive value *****PPV= Positive predictive value. Its role in stimulation of I-131 uptake & retention in DTC patient is well established (8, 14, 16, 17, 18, 19) . (8, 14, 15, 20, 21) .
In agreement with other published data (14, 15, 22, 23, 24) , a significantly higher accuracy, overall sensitivity & NPV (90.5%, 88.6% & 73.5% respectively) were noted in TSH stimulated compared to TSH suppressed groups ( 66.6%, 62%& 32.1% respectively) (P<0.05). The differences in sensitivities were more obvious in nodal rather than pulmonary lesions. The relative unsatisfactory low NPVs for TSH stimulated (73.5%) and TSH suppressed group (32.1%) is related to the low yield in detection of small pulmonary lesions in both groups. Finally a high specificity and PPV results were demonstrated due to limited number of false positive lesions in both groups (P>0.05). Beside to the additive value of TSH, interaction of site, size, metabolic activity, heterogeneity of differentiation or respiratory motion may play a role in such findings. Moreover possibility of a relatively higher TSH metabolic dependency in nodal compared to pulmonary lesions that may alternatively hold autonomic nature should be considered. This suggestion is supported by the noticed significant differences in the recorded mean values of SUVs in both groups that were significantly higher in TSH stimulated group compared to TSH suppressed group in loco-regional rather than pulmonary lesions. The diagnostic value of TG level in follow up of DTC is well established in the literature (25, 26, 27) . In the current study the mean serum TG values were significantly higher in TSH suppressed group compared to TSH stimulated group (P<0.05). The more frequent pulmonary metastases in suppressed compared to stimulated groups contribute to such finding (25, 27) . The diagnostic use of F-18 FDG PET/CT is dependent on the serum TG level in dedifferentiated thyroid cancer patients with negative I-131 WBS (8, 22, 28) . For a complete consensus to define the optimal diagnostic utility of F-18-FDG PET/CT in de-differentiated thyroid cancer the level of serum TG cut off point that provides the utmost sensitivity & specificity for its use is clinically desired. Receiver operating characteristic curve analysis was used to mark a TG cut off value that point a certain accuracy value to the imaging method and in order to determine the optimal cost effectiveness for the use of F-18-FDG PET/CT in dedifferentiated thyroid cancer. ROC curve analysis mark a significantly lower level of TG cut off point for TSH stimulated group (15 ng/ml) compared to suppressed group (21 ng/ml) (P<0.05).
Change in Restaging of recurrent De-DTC patients :-
In comparison to CT, The impact of F-18 FDG PET/CT on restaging of recurrent De-DTC patients was significantly higher in TSH stimulated group (40%) compared to TSH suppressed group (11.2%) with enhanced sensitivity and specificity in determination of nodal lesions. In contrast a significantly higher influence of CT was demonstrated in TSH suppressed 16.6 % compared to TSH stimulated group 5% due to enhanced sensitivity in determination of pulmonary lesions.
The strength of the study lies in inclusion of fairly comparable groups of patients with no significant difference in age, sex, staging as well as pathological sub-types. It shows the impact of TSH level on the overall results and lesion site related accuracy of F-18 FDG PET/CT in dedifferentiated thyroid carcinoma. Also it explore the influence of variations of TSH level on the determination of value of TG cut off point that permits utmost sensitivity & specificity of F-18 FDG PET/CT results. Finally the study determines the possible impact of variations of TSH level on the value of F-18 FDG PET/CT in respect to change in patient management.
The limitations of this prospective study include the inability to correlate F-18 FDG PET-CT results with specific molecular & immune-histochemical markers for de-differentiation that determine either the predisposing gene mutation (e.g BRAF-V600E) or subcellular molecular changes which are not applied routinely in our institute. Secondly, the accuracy of F-18 FDG PET/CT was partially but not fully established on basis of histo-pathological examination on supposed secondary lesions. Alternatively a limited follow up of TG value as well as CT results were used. However this is difficult to eliminate because of ethical & clinical concern in practice.
Thirdly this study was carried out on a relatively small number of patients with variation in duration of disease and on short-term basis. Finally the study did not consider the possible influence in variations of TSH levels in respect to the accuracy of F-18 FDG PET-CT in TSH stimulated group.
CONCLUSIONS:
High TSH seems to have site dependant enhanced F-18 FDG PET/CT efficiency in recurrent de-differentiated thyroid carcinoma patients with negative I-131 WBS and elevated TG level that is more obvious in nodal rather than pulmonary lesions. Being more sensitive, TSH stimulated F-18 FDG PET/CT, marks a lower TG cut off point compared to TSH suppressed F-18 FDG PET/CT 
